Brief: Virios Therapeutics Announces Submission Of Final Toxicology Results
15/05/2023 12:17
May 15 (Reuters) - Virios Therapeutics Inc VIRI.O :
* VIRIOS THERAPEUTICS ANNOUNCES SUBMISSION OF FINAL
TOXICOLOGY
RESULTS TO SUPPORT PROPOSED PHASE 3 PROGRAM FOR NOVEL THERAPY TO
TREAT FIBROMYALGIA
Source text for Eikon: ID:nGNX68yzz7
Further company coverage: VIRI.O
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study